Using p53 to Identify Bladder Tumors
Author Information
Author(s): Piaton E, Faÿnel J, Ruffion A, Lopez J G, Perrin P, Devonec M
Primary Institution: INSERM U.407, Université Claude Bernard Lyon I, Lyon, France
Hypothesis
Can liquid-based cytology improve p53 immunolabelling and its prognostic value in bladder tumors?
Conclusion
The study found that p53 immunolabelling in urinary samples can help identify bladder tumors with a higher risk of recurrence and progression.
Supporting Evidence
- p53 positivity was found in 17.2% of urine samples.
- High-grade tumors showed 74.1% positivity for p53.
- Recurrence was observed in 52.9% of p53-positive cases.
- Progression was noted in 35.3% of p53-positive cases.
Takeaway
Doctors can use a special test to find a protein called p53 in urine, which helps them see if a bladder tumor might get worse.
Methodology
The study analyzed 198 urine samples using liquid-based cytology and assessed p53 immunoreactivity.
Potential Biases
Potential biases may arise from the selection of patients and the interpretation of cytological results.
Limitations
The study may have limited generalizability due to the specific patient population and sample collection methods.
Participant Demographics
The study included 64 women and 134 men, aged 34 to 98 years, with a mean age of 67.3 years.
Statistical Information
P-Value
P<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website